Anti-NMDA Receptor Encephalitis clinical trials at UCSF
1 research study open to eligible people
Anti-NMDA receptor encephalitis happens when the immune system attacks the brain by mistake. UCSF is running trials to see if satralizumab can treat this illness. They are also studying the safety and behavior of the drug in the body.
Showing trials for
Pharmacodynamics Of Satralizumab In Patients With Anti-N-Methyl-D-Aspartic Acid Receptor (NMDAR) Or Anti-Leucine-Rich Glioma-Inactivated 1 (LGI1) Encephalitis
open to eligible people ages 12 years and up
The purpose of this study is to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of satralizumab in participants with anti-N-methyl-D-aspartic acid receptor (NMDAR) and anti-leucine-rich glioma-inactivated 1 (LGI1) encephalitis.
San Francisco, California and other locations
Last updated: